1. A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA. (June 2017) Authors: Gopal, A.; Levy, R.; Houot, R.; Patel, S.; Hatake, K.; Popplewell, L.; Chen, Y.; Davis, C.; Huang, B.; Cesari, R.; Thall, A.; Woolfson, A.; Bartlett, N. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). (June 2017) Authors: Chen, R.; Gibb, A.L.; Collins, G.P.; Popat, R.; El‐Sharkawi, D.; Burton, C.; Lewis, D.; Miall, F.M.; Forgie, A.; Compagnoni, A.; Andreola, G.; Brar, S.; Thall, A.; Woolfson, A.; Radford, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗